Mk13 mod 5 built by Redbull Armory on a deployment kit. Stiller mk13 Garland marked action. No optic. Comes with everything shown except for optic, and that can be negotiated if necessary. 240 rounds down the pipe. $10,500 shipped to your FFL.

Thought this might be a fun topic I don’t often see discussed here, but how about a thread dedicated to sub-caliber (anything below .22) rifles?

I recently got bit by the .17 bug, and would honestly love a .20 as well though that may be awhile yet. I have a .17 Fireball and will be picking up a .17 Ackley Bee next week, but anything sub-cal would belong here no matter how obscure. Calhoon stuff, Ackley stuff, .10s, .12s, .14s, .17s, 19s, .20s bring it all!

To start, since I’m pretty new to this stuff, I’m powder shopping for my two. I realize the .17AB and .17FB are both relatively close-ish in performance, but the prices were right so I pounced. I was initially hoping for a .17 Hornet and a Fireball, but holy hell the going prices for anything Hornet are crazy these days! About the only rifles in mass production for it would be the Savage 25, which gets mixed reviews and sells for way too much for what it is IMO. Ruger and CZ are both put of the Hornet game, and both of them sell for STOOPID money most of the time. I still want one, but it may be awhile…

So anyway, the Ackley Bee will have to do in it’s stead. If anyone else is shooting these, I’m open to powder suggestions. Benchmark and 8208 both come recommended, but are both hard to find and expensive when you can find them. I’d prefer something relatively temp sensitive and less expensive, but that combo may be a unicorn right now. TAC, CFE-BLK, H335, and VV N120/130 are less expensive options that seem to get good reviews as well, so I may order a pound of each in a bit and start load development to see what I can get.

So, what’s everyone else shooting, if anything?

I am going to start shooting steel challenge and production class and am already looking ahead and think about shooting limited and posible open at some point...I think open may be a bit much for me right now but you never know. I would like to hear from guys that are or have shot in these divisions and advise on who are some of the best builders for open and limited.

And lets just pretend money is not an issue....I've been looking for a few months now and seems from about $3500 and up is the price point for a nice limited and or race gun.

Theyre joining gas stoves in being 'regulated' (read: priced out of your budget). Wouldnt want the serfs being too comfortable.

Biden admin cracks down on air conditioners as war ...​

Fox News
https://www.foxnews.com › politics › biden-admin-crack...




1 day ago — The Biden administration announced its latest home appliance regulations this week, targeting air conditioners in an action it said would ...

This is a brand NEW 52" GA Precision Tactical Operations Drag Bag. 50" internal Length - This thing has everything. Even a padded shooting mat. Zippered pouches everywhere. Suppressor pouch. It also has padded shoulder straps that can be pulled out of one of the pouches. It is probably the best rifle bag you can buy. I have never used it. I received it a month ago. I just dont need it.

These are about $375 new (w/shipping)

Im asking $299 shipped UPS CONUS

** I know I am a new seller but I have bought a few items on this forum. I'm also a member on other forms if you need to look there..

Looks like those evil oompa loompa's are at it again folks.
I wonder if they are being contracted by that shirtless guy?



Login to view embedded media

Y’all send some prayers up for these folks. Looks like it was a doozy. Anyone on here from around there?

I keep seeing disclaimers on gunbroker auctions stating that insurance is not included and/or costs extra. Not just from private individuals but also businesses.

One in particular was concerning to see because it looked like they wouldn't accept credit card payments if you wanted to fully insure the rifle. I'm not going to buy that particular rifle, mostly because it has hit crack smoking prices, but I generally prefer credit card for these types of transactions just so I have some protection from fraud. But suppose I did buy it and it never showwd up, or showed up damaged. Would the seller be able to stop a chargeback with those terms listed?

6lbs and change H4350. 5lbs and change H1000.

$300 shipped H4350
$250 shipped H1000

Sal 504-813-2904

Burris XTR 3; 5.5-30x56mm; SCR MIL Reticle (#201210)
Burris XTR Throw Lever - Color Black (MPN: 626025)
Burris Bubble Level Anti-Cant Device (MPN: 626006)

Price: $SOLD

For sale. Local pickup near Denver CO, will not ship
2000 Federal Small Pistol primers in 3 boxes of 1k $80 per thousand, prefer to sell all together
2000 CCI Small Rifle Primers $80 per thousand
1-8 pd hodgdon CFE pistol powder $280
1-8 pd hodgdon TiteGroup powder $280
1-8pd IMR 8208 $35
2-1 pd cans of Alliant 10x reloader $70 for 2 pds
1-1 pd can of IMR SR 7625 powder $35
1-1 pd can of IMR 4350 $35
Will not ship powder or primers, local pickup only

Hate to do it but time to let these scopes go.

Schmidt Bender 4-16x50 with the Gen2XL mildot ret, illuminated, CCW turrets, NEAR manufacturing one-piece mount, tenebraex scope caps. i believe i have the box for this scope.

$2900 shipped


Schmidt Bender 4-16x42 with H37 reticle, CCW, illuminated, tenebraex caps. i bought this scope here off the hide and had the illumination installed back into it and the scope was gone through by S&B. Has not been on a gun since then.

$2800 shipped SOLD







Through the scope is the H37

$2699.00 shipped lower 48

Mounted in the ARC M-BRACE that I just sold today. No marks from the mounting - all perfect as brand new
I put on my 300N and decided it was more magnification than I want. ZS not set, so you have it as it comes.
I am more of a hunter-shooter and will go with a 4-20 ATACR that I already own.

Includes all accessories, paperwork, boxing, caps, sunshade, tool etc

No trades, thank you

Scale and V3

$1,000 shipped

Sal 504-813-2904

Have multiple bags of 6MM Creedmoor Brass. Most is LRP. 75 Hornady, 43 Starline, plus assorted other brands with a few quality brands that are Small Rifle Primer. All brass is cleaned.

Note, All Brass is Range Pickup.

Pay shipping and its yours. If you want a part, that’s also fine. I think the picture clearly shows the brands and quantity. I have it and if anyone can use it, I like them to have it.

Also, if one chooses local pickup, then obviously there are no shipping costs, it’s Free.



Now for the bait and switch. I have a partial box of Hornady A-Tips. There are 85 bullets in the box, all but one remains untouched in the original packaging. One bullet was seated in a dummy round to check chambering. Cost for the 85 bullets that also includes the polishing cloth is $50.00 plus shipping.



Also, I have some assorted 6BR, 6.5x47 and 6.5 PRC cases in small quantities. If anyone wants em, let me know. I’ll get them to you as cheaply as possible.

After kicking around the idea for the last six months or so I’ve decided to list the best rifle I’ve ever owned. I simply don’t have the time to shoot anymore.

Lone Peak Fuzion SA Mag bolt face
Foundation Centurion in black
Krieger 4 groove heavy palma 1/8 @ 28”
Hawkins bottom metal

Barrel was chambered by Travis @ TS
.115 freebore using the 6.5 prc2 reamer

The “2” designation on the reamer is +.002” @ the case web which solves the sticking issue inherent with the SAAMI chamber specs.

Also outfitted with-

Triggertech diamond trigger
Accurate AICS 7 round mag
Hawkins brake (blended & timed @ TS)
AccuTac WB-4 bipod
Foundation bipod mount

The rifle shoots lasers with no pressure issues whatsoever. I run Berger 144gr hybrids on cruise control at 3060fps

$3,500 firm

Sal- 504-813-2904

I’m gonna need a new mower soon. I have a 23 year old John Deere riding lawn mower. It’s been a damn good mower, I mean a DAMN good mower. But the deck is worn out, the front end is worn out, the hrdrostatic drive is on its last leg, my son tore the cowling, over the motor, up a long time ago, the tires won’t hold air for long, and it needs a new battery…it’s just a mess. The bad thing is, the motor is an excellent motor, and still runs great.
So…I’m gonna break it to the wife that it’s time to get a new mower.

When I retire in a couple years, I’ll be moving, and where I’m moving to has at least 2 acres. So, I’m going to be looking for a ZTR mower.

My limited knowledge about them leads me to either a XMark or a Gravely.
The XMark is obviously the most popular with the lawn care services, and that means a lot to me. It has more electronics on it. Not sure if that’s a good thing or bad. It’s probably more comfortable than the Gravely. I’m sure the XMark is a great machine.

The Gravely has good reviews, seems to be a more simple machine, less electronics, which means easier to work on, and it looks like it’s built like a frikkin tank.

One thing I don’t want is a tin foil machine. A heavy duty deck is a must. A reliable motor and drive are necessary. I don’t want the mower to spend most of its life in the shop.

Anybody have any pros or cons about either machine that they’d care to share? I’d sure love to hear which machine you’d prefer, and your whys and why nots.

It’s going to be $6000-$8000 dollars I’m sure, when it’s all said and done, so I want to make the best decision. I’m going to continue to read reviews before I buy. I just thought I’d get your $0.02 worth as well.
Thanks.

LMAO

I was wearing one of my Sniper's Hide sweat shirts, standing in the checkout line at Lowes. As I turned to leave and old guy said, "Hey I like your shirt" I told him I shoot long range and he brightened up and mentioned he was headed up to Raton NM to the NRA Whittington center, had I heard of it? I told him I got certified as a Barrett Armorer there and shot my M82 out to 1000 yrds. He told me he had hit the White Buffalo at 1350 yards and that he was going out to meet up with members of his old team from Viet Nam, headed up by Col. Robert Brown. We chatted for a moment more then I wished him well and God Bless.

I'm kicking my ass for not inviting him to go shooting, probably could learn a lot.

we all know the next one is in the works. prob for the '24 election cycle. bet your ass that gun shops and ranges won't be declared "essential" this trip.

$1699.00 shipped lower 48
mounted carefully in SPUHR (listed) never fielded or set ZS. Only time outdoors was to take these pics today. No marks from mounting. Includes all orig boxing, paperwork and acc

excellent scope, selling Barrett SMR is only reason for sale

You guys are going to really need to get this one - this Marburg here has a 90% mortality. Just spread from New Guinea to Tanzania. But NO WORRIES folks, BioNTech, the same awesome innovators that brought us the Covid vaccine with 95% efficacy, has already a superb mRNA Marburg vaccine ready to go as of end of January. Plus, the NIH has done its first human trials in January with Marburg vaccines at Walter Reed.
And - low and behold - an outbreak of Marburg in New Guinea in February just happened!!! What are the odds!!

Published end of January:
https://www.linkedin.com › pulse › vaccine-production-marburg-has-right-stuff-christian-korner

Vaccine production: Marburg has the right stuff​

Christian Korner

Christian Korner​

Head of Pharma Business US at Siemens​

Published Jan 25, 2023
+ Follow
How quickly “normal life” can be resumed depends in part on how quickly the population can be vaccinated. One of the vaccinations that provides particularly good protection against Covid-19 is the BNT162b2 vaccine from Mainz-based biotech company BioNTech SE. To scale-up the manufacturing capacity further, the company began production in Marburg which is one of the largest mRNA-based vaccine manufacturing sites worldwide. To achieve this, BioNTech drew on the expertise available at Siemens to enable it to provide more of the sought-after vaccine as quickly as possible.
BioNTech manufactures BNT162b2 in collaboration with US pharmaceutical specialist Pfizer. The company has started manufacturing in Marburg, in the German state of Hesse. In the fall of 2020, it took over a production facility for biotech products from Novartis for this purpose. That gives it a good basis for successful vaccine production: The plant at Marburg comes with an ultramodern production facility for recombinant proteins. The relevant expertise is also available, since BioNTech also acquired a highly qualified employee base along with the production facility, all of whom are experienced in developing new technologies. The facility in Marburg had been producing influenza vaccines based on flu cell culture, then changed over to recombinant proteins for cancer treatments and now manufactures mRNA vaccine. Siemens is providing support with the switchover to vaccine production. There are two reasons for this: Siemens already knows the Marburg facility very well and has worked with it previously on activities including automation of vaccine production development. The two companies can also look back on a number of projects they have already completed together in the previous years.

Full speed ahead thanks to total commitment
Everyone involved in the project knew how important it was: The sooner production could start; the sooner more vaccine doses will be available. The hopes of society therefore depend on this project: German Chancellor Angela Merkel even commented at the Federal Press Conference on February 1, 2021, that “Marburg will make the difference.” A project of this magnitude normally takes about a year, but in this case the participants completed the conversion in just five months. Main components of the new manufacturing execution system (MES) were completed in only 2.5 months. Andreas Haag, in charge of the project for Siemens, observes: “One factor that made it possible was the high level of cooperation between the teams and outstanding commitment by everyone involved: They all worked overtime and took no leave in order to advance the project as fast as possible.” And under pandemic conditions, too: Things that would normally be done by working together on-site were instead performed largely by a decentralized team based in separate home offices. The project was a complete success, since the new Electronic Batch Records (eBPR) as part of the manufacturing execution system (MES) was ready to use in just 2.5 months.
What was converted?
During the project to switch the Marburg plant over to production of mRNA-based vaccines, Siemens focused on future viability. All the improvements are Industrie 4.0-compatible. One of the challenges with the conversion was the fact that it involved switching from rigid to mobile production with many single-use components. For example, it meant a whole raft of components had to be registered. That was one reason why the project partners decided to switch to paperless production. At the same time, working with mRNA meant a higher clean room class than was previously required in the facility. Paper is now an avoidable “contamination factor” that doesn’t arise with digital production. That was the basis for opting for the Opcenter Execution Pharma solution from Siemens as the new MES. This solution enables complete paperless manufacturing and fully electronic batch recording. Seamlessly integrating automation solutions makes it possible to develop, optimize, and manage production processes automatically. Because mRNA processes include a lot of manual stages – weighing, for example – operators require guidance through these. This is provided by the workflow management component of the software. Opcenter Execution Pharma orchestrates the various sections of the system to ensure efficient production. The software enables real-time production and the provision and analysis of process and quality information in order to optimize production activities from initial order to finished product.
To automate the facility, all systems were converted to the latest version of Simatic PCS 7. The powerful, flexible, and scalable distributed control system steers and controls all the processes in the plant and takes digitalization to field level. Although most parts of the new MES are now in place, additional automation components are still in progress.
In focus: paperless production
Paperless production offers advantages over traditional procedures in the pharmaceutical industry in particular: Process data, conditions, and results are recorded in detail to ensure processes are more resistant to error, in other words, they are made more robust and less susceptible to deviations. At the same time, the tasks of data input and documentation are now less complex. Electronic Master Batch Record Management enables users to create, execute, review, and release Master Batch Records (MBR), and Electronic Batch Records (eBR) are made faster. The individuals in charge can easily monitor, observe and, if necessary, record every stage of production and every base material. Testing is based on the principle of “review by exception” – in other words, deviations are dealt with when the system recognizes them based on exception rules. That makes the testing process less labor-intensive and much faster, since otherwise the individuals in charge would have to check several thousand pages on paper. As a result, digital production is a significant factor in making the process faster and improving quality.
Unity is strength
To ensure a smooth start to production, Siemens supported the implementation of the system at BioNTech with Hypercare and a 24/7 project-based standby arrangement. That means the employees in production could request help with operating the system from the manufacturer at any time of the day or night. The project is a complete success for both parties and the production was able to start before the end of February with the production of the drug substance: the mRNA. “We want to thank Siemens for their excellent collaboration on this project and the huge effort they put in, often exceeding 100 percent,” says Valeska Schilling, Head of Production Department at BioNTech Marburg.
62

-------------------------------------------------------------------​

Marburg vaccine shows promising results in first-in-human study​

Colorized scanning electron micrograph of Marburg virus particles (blue) both budding and attached to the surface of infected VERO E6 cells (orange).

What​

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could someday be an important tool to respond to Marburg virus outbreaks.

This first-in-human, Phase 1 study tested an experimental MARV vaccine candidate, known as cAd3-Marburg, which was developed at NIAID’s Vaccine Research Center (VRC). This vaccine uses a modified chimpanzee adenovirus called cAd3, which can no longer replicate or infect cells, and displays a glycoprotein found on the surface of MARV to induce immune responses against the virus. The cAd3 vaccine platform demonstrated a good safety profile in prior clinical trials when used in investigational Ebola virus and Sudan virus vaccines developed by the VRC.

MARV, a filovirus in the same family as Ebola virus, causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals. Many scientists think that MARV disease outbreaks in humans begin by when the virus makes the jump from its primary animal host, which is likely to be certain chronically infected bats in sub-Saharan Africa. The symptoms of MARV disease are akin to those seen with Ebola virus disease and can include fever, headache, chills, rash, abdominal pain, vomiting, and diarrhea. As the disease progresses, patients may suffer from multiple organ dysfunction, delirium, and significant bleeding from the gastrointestinal tract or other sites that may result in death. No approved vaccines or specific therapies are available for MARV disease, aside from supportive care. While some experimental vaccines have previously been tested, none have proven to be both highly effective and to provide durable protection. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling outbreaks.

In this study, 40 healthy adult volunteers were enrolled at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland. They received a single dose of either a low dose of the vaccine (1x1010 particle units) or a higher dose (1x1011 particle units). For safety, the volunteers were enrolled in a dose-escalation plan. Three participants received the lower dose. Then, when they did not exhibit severe adverse reactions after the first seven days, the trial proceeded to enroll the remaining 17 volunteers. The same procedure was also used for the higher dose group. Volunteers were monitored for adverse reactions to the investigational vaccine and evaluated at regular intervals for 48 weeks to track their immune responses.

The trial’s safety results were encouraging: There were no serious adverse events, and the experimental vaccine was well-tolerated. One participant in the higher dose group developed a fever following vaccination, but it resolved by the following day. In addition, the investigational vaccine appeared to induce strong, long-lasting immunity to the MARV glycoprotein: 95% of participants in the trial exhibited a robust antibody response after vaccination, and 70% maintained that response for more than 48 weeks.

Plans are in place to conduct further trials of the cAd3-Marburg vaccine in Ghana, Kenya, Uganda, and the United States. If additional data supports the promising results seen in the Phase 1 trial, the cAd3-Marburg virus vaccine could someday be used in emergency responses to MARV outbreaks.

Article​

M Hamer et al. Safety, tolerability, and immunogenicity of the Marburg chimpanzee adenovirus vector vaccine (cAd3-Marburg) in healthy adults: a phase 1, open-label, dose-escalation trial. The Lancet DOI: 10.1016/S0140-6736(22)02400-X (2023).

Who​

Lesia Dropulic, M.D., chief of the Clinical Trials Program at NIAID’s Vaccine Research Center, is available for comment.

Contact​

To schedule interviews, please contact Elizabeth Deatrick, (301) 402-1663, [email protected].

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
--------------

An outbreak of the deadly Marburg virus has been confirmed. Here's what you need to know​

There is no vaccine or drug treatment for the virus, which has killed at least 9 people in Equatorial Guinea​

Stephanie Hogan · CBC News · Posted: Feb 17, 2023 3:00 AM CST | Last Updated: February 18

Racing to contain Marburg virus outbreak in Equatorial Guinea​

1 month ago
Duration 2:13
There's a race to contain an outbreak of Marburg disease — caused by an Ebola-related virus — in Equatorial Guinea, where at least nine people have died. There's no cure for the deadly disease and development of a vaccine was paused years ago.
The World Health Organization this week confirmed an outbreak of the Marburg virus in Equatorial Guinea — the first time the tiny country in Central Africa has seen cases of the deadly illness.
Marburg, which is related to Ebola, is already being blamed for at least nine deaths in the country, and another 16 suspected cases are being investigated.
Without treatment, Marburg can be fatal in up to 88 per cent of people.
A 2004-05 outbreak in Angola killed 90 per cent of the 252 confirmed cases.
Here is what you need to know about this rare but dangerous virus.

What is Marburg virus?​

Marburg virus is believed to have originated in African fruit bats. It was first identified in 1967 in Germany and the former Yugoslavia, according to the U.S. Centers for Disease Control and Prevention, among people who had been working with green monkeys that had been imported from Uganda.
According to the World Health Organization (WHO), people can contract the virus through prolonged exposure in mines or caves where the bat colonies live.
The virus spreads between humans through direct contact with blood or other bodily fluids of an infected individual, or with surfaces contaminated with the virus, such as clothing or bed sheets.
Marburg is not airborne.

Marburg virus is believed to have originated in the African fruit bat, and it can be contracted by humans through prolonged exposure to mines or caves where the animal lives. (Bob Child/The Associated Press)

What are the symptoms?​

Symptoms may begin "abruptly," according to WHO, and include high fever, severe headache and malaise. Muscle aches and pains are also common.
"It can impact every organ, and it essentially will cause a shock-like syndrome," said Dr. Isaac Bogoch, an infectious diseases specialist at Toronto General Hospital.
He said the virus can also cause gastrointestinal complications and a predilection to easy bleeding.
WHO says a rash can appear in the first seven days, and the central nervous system can be affected, resulting in confusion, aggression and irritability.
If death occurs, it generally happens eight to nine days after onset, following severe blood loss and shock.

An electron microscope photo of the Marburg virus. An outbreak of the deadly virus has been confirmed in the Central African country of Equatorial Guinea. (Thomas Geisbert/University of Texas Medical Branch)

How is it treated?​

There is currently no vaccine for Marburg and no therapeutics to treat it. But patients can be helped.
"They need supportive care," Bogoch said, including intravenous fluids, as well as electrolyte balance and monitoring. "That can significantly lower the mortality rate," he said.

Where are the confirmed cases now?​

Cases connected to the current outbreak in Equatorial Guinea were first detected in the northern province of Kie-Ntem, near the border with Cameroon.
The outbreak was confirmed after samples were sent to a lab in Senegal. Suspected cases from Cameroon and Gabon were also investigated but found not to be Marburg, WHO said.
But that doesn't mean there aren't more Marburg cases.

• Uganda hospital worker dies of Marburg virus

"When new diseases appear in new locations, we are often just seeing a piece of the picture," said Dr. Kamran Khan, the founder and CEO of Toronto-based BlueDot, a company that tracks infectious diseases around the world.
He said there are probably more cases and more contacts than the official numbers would indicate, noting that Equatorial Guinea is one of the most resource limited countries in the world.
"Its capabilities in terms of its health-care system, its public health infrastructure for countering an outbreak, are pretty limited," he said.

---

WHO said it is sending medical experts to help local officials in Equatorial Guinea, along with protective equipment for hundreds of workers.
"Surveillance in the field has been intensified," said George Ameh, WHO's country representative in Equatorial Guinea.
"Contact tracing, as you know, is a cornerstone of the response. We have ... redeployed the COVID-19 teams that were there for contact tracing and quickly retrofitted them to really help us out."
WHO director general Tedros Adhanom Ghebreyesus said the agency is also supporting the governments of Cameroon and Gabon "to prepare, to rapidly detect, isolate and provide care for any suspected cases."
WATCH | WHO is deploying teams to Equatorial Guinea to deal with Marburg outbreak:

Trying to contain the Marburg virus​

1 month ago
Duration 0:56
WHO director general Tedros Adhanom Ghebreyesus says the agency is sending teams and supplies to the Central African country of Equatorial Guinea to try to contain the current outbreak of the deadly Marburg virus.

Is there a concern about spread?​

The current Marburg outbreak appears to be regional, but Bogoch notes that infection on one part of the Earth can quickly land on another part in a very short time frame.
"We saw that with, for example, the West African Ebola virus epidemic — which started off as a very small outbreak, turned into a multi-country, multi-year outbreak that took a long time to get under control."
Khan of BlueDot said Equatorial Guinea is going to need international assistance to be able to get ahead of this outbreak. "Today, it's a concern for the region and some of the neighbouring countries. But if we don't get ahead of this, this could become a broader concern for the global community."

Should people living in Canada be worried?​

There's probably no immediate concern about a case of Marburg being found in Canada.
"I think this is important for Canadians to understand that the likelihood of a case of Marburg showing up in Canada right now is exceedingly low," Kahn said. But he said it's important to be aware of the larger issue — which is that "there are more outbreaks appearing in the world today, they are becoming larger, they are becoming more dangerous and disruptive."
Bogoch said while the current Marburg outbreak is small, now is the time to jump on it so that it doesn't expand.

--------------------------------------------------------
Well, its already to Tanzania, but obviously the Canadian press weren't on top of how our astute virologists saw this coming and were doing the first vaccine clinical trials in January. And the head dude at Siemens was appropriately proud of this as can be seen in his January 25 article above.

Just amazing, almost like these guys had a crystal ball. Thank goodness the WHO is finally (or will be within a week or so) in charge of everything so we don't have to worry about local bureacracies or even the wisdom of supersmart Joe BIden interfering one bit!

I’m selling my T6Xi 5-30x56 with the SCR2-Mil Reticle.

The scope is new… and has not been in rings and mounted. It comes with the original box and all of the goodies.

It’s a very nice scope, but it’s a little too big for what I wanted to do with it.

Asking $1600 shipped. I’m not interested in trades.

If you have any questions or want to see more pics, please let me know.

Thanks for looking, Matt